Monopar Therapeutics

MNPR54

$5.250.00%$0.00

MNPR54

$5.25

0.00%$0.00

Performance History

Key Stats
Open	$5.84
Prev. Close	$5.71
EPS	-2.30
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$19.36M
PE Ratio	-

	LOW	HIGH
Day Range	5.49	5.85
52 Week Range	1.37	8.65

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.30

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc (MNPR) is a biopharmaceutical company that focuses on developing innovative therapeutics for patients with high unmet medical needs. The company's primary goal is to provide effective treatment options for cancer patients and improve their overall outcomes. Monopar Therapeutics has a diverse pipeline of promising drug candidates that target different types of cancer, including solid tumors and hematological malignancies.

One of the key highlights of Monopar Therapeutics is its dedication to precision medicine. The company employs an individualized approach to treatment, leveraging various biomarkers and genetic information to identify patients who are most likely to benefit from its therapies. This personalized approach has the potential to revolutionize cancer treatment and significantly improve patient outcomes.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Headquarters: Wilmette
Employees: 11
Exchange: NASDAQ

Keep an eye on Monopar Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Monopar Therapeutics 's (MNPR) price per share?

The current price per share for Monopar Therapeutics (MNPR) is $5.25. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Monopar Therapeutics (MNPR)?

For Monopar Therapeutics (MNPR), the 52-week high is $8.65, which is 64.76% from the current price. The 52-week low is $1.37, the current price is 283.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Monopar Therapeutics (MNPR) a growth stock?

Monopar Therapeutics (MNPR) has shown an average price growth of -2.84% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Monopar Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Monopar Therapeutics (MNPR) stock price performance year to date (YTD)?

As of the latest data, Monopar Therapeutics (MNPR) has a year-to-date price change of 183.78%. Over the past month, the stock has experienced a price change of 20.14%. Over the last three months, the change has been 65.35%. Over the past six months, the figure is 66.14%.

help

Is Monopar Therapeutics (MNPR) a profitable company?

Monopar Therapeutics (MNPR) has a net income of -$8.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$8.83M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Monopar Therapeutics (MNPR)?

Monopar Therapeutics (MNPR) has a market capitalization of $19.36M. The average daily trading volume is 5.25, indicating the stock's liquidity and investor engagement.